Venatorx Pharmaceuticals develops a novel anti-infectives to treat multi-drug-resistant bacterial infections and viral infections.
VenatoRx is a private pharmaceutical company focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant bacterial infections and hard-to-treat viral infections. Founded in 2010, VenatoRx has built a world-class in-house R&D organization that has filed over 100 patents spanning multiple research programs. It has received significant funding awards from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH); Wellcome Trust; the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Service (HHS); the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA); and CARB-X, and as well as private equity investments from Versant Ventures, Abingworth, and Foresite Capital.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 25, 2017 | Series B | $42M | 1 |
![]() |
— | Detail |
Apr 7, 2014 | Grant | $6M | 1 |
![]() |
— | Detail |
Jun 26, 2010 | Grant | $4.30M | 1 |
![]() |
— | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Jun 18, 2018
![]() |
Initial Coin Offering | $20M | Bitcoin | — |
Nov 13, 2017
![]() |
Initial Coin Offering | $41M | Asset Management | — |
Nov 2, 2017
![]() |
Initial Coin Offering | $21M | Cryptocurrency | — |
Nov 1, 2017
![]() |
Initial Coin Offering | $1M | Blockchain | — |
Oct 11, 2017
![]() |
Initial Coin Offering | $37M | Bitcoin | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Series B |
![]() |
Yes | Grant |